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Key points 
• A seven-gene signature is derived which can identify myeloma patients who respond 
better to bortezomib- or to lenalidomide-based therapy. 
• Treatment according to the signature is non-inferior to treatment with combined 
bortezomib, lenalidomide, and dexamethasone. 
  
2 
 
 
Abstract 
Improving outcomes in multiple myeloma will not only involve development of new 
therapies, but better use of existing treatments. We performed RNA sequencing (RNA-Seq) 
on samples from newly diagnosed patients enrolled into the phase II PADIMAC 
(Bortezomib, Adriamycin, and Dexamethasone (PAD) Therapy for Previously Untreated 
Patients with Multiple Myeloma: Impact of Minimal Residual Disease (MRD) in Patients 
with Deferred ASCT) study. Using synthetic annealing and the Large-Margin-Nearest-
Neighbor algorithm, we developed and trained a seven-gene signature to predict treatment 
outcome. We tested the signature on independent cohorts treated with bortezomib- and 
lenalidomide-based therapies. The signature was capable of distinguishing which patients 
would respond better to which regimen. In the CoMMpass (relating Clinical outcomes in 
Multiple Myeloma to personal assessment of genetic profile) dataset, patients who were 
treated correctly according to the signature had a better progression-free survival (median 
20.1 months versus not reached; hazard ratio 0.40; confidence interval 0.23-0.72; p=0.0012) 
and overall survival (median 30.7 months versus not reached; hazard ratio 0.41; confidence 
interval 0.21-0.80; p=0.0049) than those who were not. Indeed, the outcome for these 
correctly treated patients was non-inferior to those treated with combined bortezomib, 
lenalidomide, and dexamethasone, arguably the standard of care in the United States, but not 
widely available elsewhere. The small size of the signature will facilitate clinical translation, 
thus enabling more targeted drug regimens to be delivered in myeloma. 
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Introduction 
Multiple myeloma is a plasma cell neoplasm characterised by lytic bone lesions, 
hypercalcemia, renal impairment and bone marrow failure. Although outcomes have 
improved in recent years with the introduction of novel agents, the disease remains incurable 
and clinical responses display considerable heterogeneity.1,2 Further improvements will not 
only come from introduction of new drugs but from better use of existing drugs. Younger, 
fitter patients are usually treated with a drug combination involving a proteasome inhibitor 
(PI) and/or an immunomodulatory drug (IMiD) followed by high-dose melphalan therapy 
with autologous stem cell transplant (ASCT). For transplant-ineligible patients, recent trial 
data suggest that the treatment of choice may be a combination of the PI, bortezomib 
(Velcade, Millennium Pharmaceuticals, Cambridge, MA), the IMiD, lenalidomide (Revlimid, 
Celgene, Summit, NJ), and dexamethasone (VRD).3 However, this combination is expensive 
and is not funded in most countries outside the United States (US). Furthermore, for very frail 
patients, three-drug combinations may prove too toxic. 
It is possible that treatment outcomes in myeloma might be improved by the application of 
precision medicine, i.e. the rational selection of drugs based on the biology of each patient’s 
tumour. Several studies have demonstrated the potential of using transcriptomic data to 
derive prognostic information in myeloma.4-6 Signatures can be usefully combined,7 but are 
generally agnostic to treatment4,5,8-12 and their main clinical utility is likely to be the 
identification of patients who may benefit from trials for high-risk disease. We sought to 
derive a signature that could predict responses to specific therapies. 
The phase II study of Bortezomib, Adriamycin, and Dexamethasone (PAD) therapy for 
previously untreated patients with multiple myeloma: Impact of minimal residual disease 
(MRD) in patients with deferred ASCT (PADIMAC) was designed to examine whether 
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patients with good responses to PAD could safely avoid upfront ASCT. We employed RNA-
sequencing (RNA-Seq) on available good-quality RNA from enrolled patients and derived a 
training dataset from patients with sustained deep responses in the absence of ASCT. We thus 
generated a signature for predicting bortezomib-responsiveness in myeloma patients not 
receiving ASCT. When tested in independent datasets, the signature performed well, 
identifying patients who benefited from bortezomib-based treatment in the absence of an 
IMiD. Furthermore, when tested on lenalidomide-dexamethasone (RD) treated patients, the 
signature performed in a reciprocal fashion, suggesting that it could be used as a binary 
classifier to choose between bortezomib-based treatment and RD. Patients who had been 
treated correctly according to the signature classification had a superior survival to those who 
had not. Indeed, in the relating Clinical outcomes in Multiple Myeloma to personal 
assessment of genetic profile (CoMMpass) dataset, correctly treated patients receiving either 
bortezomib-based therapy (without IMiD) or receiving RD (without bortezomib) had a non-
inferior survival to those treated with VRD. This suggests that our signature could be 
employed to improve the safety and cost-effectiveness of myeloma therapy without 
compromising outcomes. 
Materials and Methods 
Sample accrual and processing and data generation 
Sample accrual and RNA isolation 
RNA of sufficient quality for RNA-Seq was available from 44 patients treated on the 
PADIMAC trial (ISRCTN03381785). The trial protocol is described in the Supplementary 
Materials. PADIMAC was conducted in accordance with the Declaration of Helsinki and 
Good Clinical Practice guidelines and was approved by the NHS National Research Ethics 
Service. Participants provided written informed consent. Patient registration and trial 
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management were performed by the Cancer Research UK and University College London 
Cancer Trials Centre. All patients had newly diagnosed untreated myeloma, Eastern Co-
operative Oncology Group performance status 0-3, and were eligible for ASCT.  Total RNA 
was isolated using standard methodology, as described in the Supplementary Materials. 
Identification of mutations and gene expression 
Standard methods were used to identify mutations and determine gene expression. Detailed 
methodology is described in the Supplementary Materials and Table S1. Briefly, reads were 
mapped with TopHat13 and aligned with Samtools.14 Single nucleotide variants (SNVs) and 
small indels were identified using VarScan15,16 and RNA fusions were identified using 
FusionCatcher.17 Read counts were generated with the Rsubread package.18,19 Raw and count 
level data have been uploaded to Gene Expression Omnibus (GEO), reference GSE116324. 
Differentially expressed genes were identified using DESeq220-22 and the Gage23 and 
Pathview24,25 packages were used for pathway analysis. 
Machine learning 
Selection of test datasets 
Test RNA-Seq datasets were derived from CoMMpass (https://research.themmrf.org/). 
Microarray test sets were obtained for relapsed/refractory patients treated with bortezomib26 
(GEO reference GSE9782), plasma cell leukemia (PCL) patients treated with RD27 
(GSE39925), and newly diagnosed myeloma patients treated with PAD followed by ASCT28 
(GSE19784). We refer to these data as the Millennium, PCL, and HOVON/GMMG datasets, 
respectively. 
Data pre-processing, training, validation, and testing 
RNA-Seq counts were normalized and corrected for heteroscedasity according to published 
methods.29-35 Potential signature genes were identified from the PADIMAC dataset by an 
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empirical Bayes method,36 then selected as described using synthetic annealing 37 with an 
error rate determined by a support vector machine implemented from the e1071 package 
(https://cran.r-project.org/web/packages/e1071/index.html). 
Signature assignments were made using the Large Margin Nearest Neighbors (LMNN) 
algorithm.38 Performance within the PADIMAC dataset was checked by ten-fold cross-
validation. For external testing, all PADIMAC data were used for training, with an initial 
50:50 split into a training and internal validation set that was fixed for all testing. R and 
Matlab scripts replicating this process have been included with the Supplementary Materials. 
All the CoMMpass, Millennium, PCL, or HOVON/GMMG data were used for testing. To 
determine the robustness of the signature performance in each case, a form of permutation 
testing was used, as described in the Supplementary Materials. 
Statistical considerations 
Null and observed assignments were compared using the Mann-Whitney-Wilcoxon test. 
Survival was compared using the Cox proportional hazards model. P-values of 0.05 or less 
were considered significant. 
Results 
Initial assessment of PADIMAC data excludes a mutation-based classifier 
We performed RNA-Seq on purified CD138+ plasma cells from a cohort of 44 patients 
treated on the PADIMAC trial. Clinical data are shown in Table S2. We first explored the 
possibility of using a mutation-based classifier for bortezomib-responsiveness. We identified 
fusion and SNV transcripts from the RNA-Seq data (Figures 1A and 1B and Tables S3 and 
S4). There were 0-8 fusions in each sample with a median of one (Figure 1A). Expected IgH-
WHSC1 fusions were detected from t(4;14) patients (Table S3). There was a median of nine 
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SNVs per patient in coding regions, which is lower than seen in previous DNA sequencing 
studies.39-42 This may reflect reduced expression from mutant alleles43 as well as a failure to 
detect mutations in the furthest 5’ regions of some genes. Nevertheless, we identified many of 
the known driver mutations in myeloma (Figure 1B and Table S4). Other known drivers were 
not mutated in our cohort, which may be related to sample size or may reflect lack of 
expression of mutated alleles.43 
Overall, 45.5% of patients in the cohort achieved very good partial remission (VGPR) or 
better following PAD induction (Table S2). We defined a “bortezomib-good” group, namely 
patients who achieved a VGPR or better and who were progression-free at one year without 
ASCT (13/44; 29.5%). We termed the remaining patients “bortezomib-standard” (31/44; 
70.5%). There were no associations between these groups and age, International Staging 
System (ISS), or myeloma type (Table S5). We also saw no significant associations between 
bortezomib-responsiveness and the presence of key cytogenetic, SNV, and translocation 
events (Table S6). There were trends towards significant associations between the 
bortezomib-good group and (a) the presence of any translocation and (b) the presence of a 
beta2-microglobulin translocation (Table S6). However, we did not feel that these 
associations were sufficiently strong for predicting clinical outcomes. We therefore turned to 
expression profiling.  
Derivation of a seven-gene bortezomib-response signature 
Expression of target genes known to be differentially expressed using microarray44 and 
qPCR45 technologies in the Translocation-Cyclin D (TC) classification was consistent with 
that previously described (Figure 1C),44 confirming the utility of RNA-Seq for measuring 
relative gene expression in myeloma. We therefore proceeded to identify a gene signature for 
bortezomib-responsiveness. We ranked potential genes using synthetic annealing37 (Figures 
8 
 
 
S1 and S2). Derived signatures comprising 4-11 genes performed better than permuted 
assignments in cross-validation of PADIMAC data using the LMNN algorithm (Figures S3 
and S4; Matthews Correlation Coefficient (MCC) median 0.55 versus -0.045, Mann-Whitney 
U 0, p=0.00090, two-tailed, Figure S4A; F-measure median 0.67 versus 0.25, Mann-Whitney 
U 0, p=0.00090, two-tailed, Figure S4B). Of these signatures, the best performing was the 
seven-gene signature (Figure 2A). As training of the LMNN algorithm parameters involves 
splitting the training set into a training and internal validation set (Figure S2), we checked 
that the seven-gene signature was robust by performing multiple (n=100) training/validation 
splits and comparing performance with permuted assignments (n=100) during cross-
validation. The observed assignments had higher MCC and F-measures than the null 
assignments (MCC median 0.50 versus 0.0054, Mann-Whitney U 8, p=2.85x10-34, two-tailed, 
Figure 2B; F-measure median 0.64 versus 0.26, Mann-Whitney U 3, p=2.42x10-34, two-
tailed, Figure 2C), confirming that the signature performed well regardless of the 
training/validation split. 
The genes comprising the signature are EMC9, FAM171B, PLEK, MYO9B, RCN3, FLNB, 
KIF1C (Table S7). We did not see enrichment of these genes within the pathway genesets 
from the Molecular Signatures Database46-48 
(http://software.broadinstitute.org/gsea/msigdb/annotate.jsp; C2 collection). However, at least 
three of the proteins (EMC9, RCN3, and KIF1C) are associated with the endoplasmic 
reticulum and three others (PLEK, MYO9B, and FLNB) interact with actin filaments. 
Furthermore, three genes (EMC9, MYO9B, and KIF1C) associate positively with 
proliferation in myeloma.10 Despite the lack of objective pathway enrichment in our 
signature, supervised analysis of the RNA-Seq data as a whole did reveal pathways 
upregulated in the bortezomib-good patients (Table S8). 
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The seven-gene signature is predictive of outcome of bortezomib-treated patients in the 
independent CoMMpass dataset 
To enable testing of our signature in an independent external dataset, we extracted RNA-Seq 
data from CoMMpass. We selected previously untreated patients who did not proceed to 
ASCT, as none of the bortezomib-good patients had received transplant. There were 147 such 
bortezomib-treated patients (who had received no IMiD), 40 RD patients, and 208 VRD 
patients for whom RNA-Seq data were available (Tables S9-S11). There were a few 
differences in clinical features between the groups. PADIMAC patients, being transplant-
eligible, were younger than all the CoMMpass cohorts (Figures S5-S7). VRD-treated patients 
in CoMMpass were younger than the bortezomib-treated and RD cohorts (Figures S9 and 
S10). RD-treated patients had higher rates of del13 than PADIMAC or bortezomib-treated 
patients and a lower rate of t(4;14) than bortezomib-treated patients (figures S6 and S8). 
There were no differences in ISS stage between the groups (figures S5-S10). 
We trained our seven-gene signature on the PADIMAC data and tested its ability to identify 
patients who would benefit from bortezomib-based therapy within CoMMpass (Figure S11). 
Patients who received bortezomib-based therapy and were assigned to the bortezomib-good 
group had a better progression-free survival (PFS) than those assigned to the bortezomib-
standard group (Figure 2D; Table 1, row 1). The randomization seed for the PADIMAC 
training/validation split had been fixed prior to testing. To ensure that the predictive ability of 
the signature was robust, we performed multiple additional training/validation splits of the 
PADIMAC training set and compared the resulting assignments in the CoMMpass test set 
with permuted assignments that formed a null dataset. As expected for a robust signature, 
hazard ratios (HRs) for the predicted bortezomib-good patients were lower than the HRs from 
random predictions (Figure 2E; Table 2, row 1). 
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The seven-gene signature has reciprocal performance in RD-treated patients and has 
the potential to select therapy 
To distinguish between the signature acting as a general predictor of good-prognosis disease 
and as a specific predictor of bortezomib-sensitive disease, we tested it in RD-treated 
patients. We reasoned that, if the signature were bortezomib-specific, the survival of RD-
patients assigned to the bortezomib-good would be no better than those assigned to the 
bortezomib-standard groups. To our surprise, RD-treated patients assigned to the bortezomib-
good group in fact had an inferior PFS to those assigned to the bortezomib-standard group 
(Figure 3A; Table 1, row 2). Whilst the difference was not significant, those assigned to the 
bortezomib-good group across repeated training/validation splits had consistently lower 
survival, with higher hazard ratios (HRs) than those obtained by permuting the assignments 
(Figure 3B; Table 2, row 2). 
The implication of these findings is that patients predicted to do well with bortezomib by our 
signature do poorly when treated with RD and vice versa. Hence the seven-gene signature 
could be used as a binary classifier to rationally choose between bortezomib-based therapy 
and RD. To test this, we selected CoMMpass patients treated with bortezomib-based therapy 
or with RD and assigned each to a bortezomib-best or lenalidomide-best group. We then 
compared survival between those patients who received the predicted best treatment with 
those who did not. Patients who received the correct therapy had a superior PFS (Figure 3C; 
Table 1, row 3) and overall survival (OS; Figure 3D; Table 1, row 4). The incorrectly treated 
patients had a median PFS of 20.1 months and a median OS of 31.2 months, whereas the 
median PFS and OS were not reached for correctly treated patients. These predictions were 
again robust to the initial training/validation split of the PADIMAC dataset (Figure S12; 
Table 2, rows 3 and 4). 
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We excluded the possibility that the signature was acting as a surrogate for clinical features. 
We saw no association between signature assignment and key cytogenetic events (p=0.13; 
Fisher’s exact test; Table S12) and in multivariate Cox regression, ideal treatment according 
to the signature retained significance for survival when age, ISS, or myeloma subtype were 
taken into account (Tables S13, rows 1 and 2). 
Because of the finding of proliferative genes in our signature, we also wanted to check that it 
was not acting as a surrogate for the gene-expression based proliferation index (GPI50) 
signature10 or other prognostic signatures. As these signatures have not, to our knowledge, 
been applied to RNA-Seq data previously, we first tested that they could be applied to the 
CoMMpass dataset. Indeed, when all of the GPI50, University of Arkansas for Medical 
Sciences (UAMS70), Erasmus University Medical Centre (EMC92), and Intergroupe 
Francophone du Myélome (IFM15) signatures4-6,10 were applied to CoMMpass, the 
distribution of scores was similar to that seen in microarray datasets5 (Figures S13A, S13C, 
S3E, and S13G). Furthermore, all signatures retained prognostic significance using thresholds 
equivalent to those previously published5 (Figures S13B, S13D, S13F, S13H). Having 
established that these prognostic signatures were effective in RNA-Seq data, we examined 
whether there was any association between their assignments and the assignments of our 
seven-gene signature. None was seen (Table S14). Furthermore, receiving ideal treatment 
according to the seven-gene signature retained its prognostic significance even in a 
multivariate analysis including these signatures (Table S15). 
A recent trial reported the superiority of VRD over RD in transplant-ineligible patients,3 but 
VRD treatment is not currently funded widely outside the US. We wondered whether 
rationally selected therapy could be a cost-effective alternative to this gold-standard 
treatment. We first demonstrated that VRD was superior to unselected bortezomib-based 
treatment or RD in CoMMpass (Figure S14; Table 1, rows 5 and 6). We then compared the 
12 
 
 
survival of patients treated correctly according to our signature with the survival of all 
patients treated with VRD in CoMMpass. There was no statistically significant difference in 
OS (Figure 3E; Table 1, row 7) or PFS (Figure S15A; Table 1, row 8) between patients 
treated correctly with bortezomib or RD and those treated with VRD. This was also true in a 
multivariate analysis incorporating clinical features (Table S13, rows 3 and 4). We also 
compared the outcome of CoMMpass patients treated correctly with bortezomib according to 
the signature (without transplant) and all patients receiving bortezomib-based induction 
followed by ASCT. Interestingly, there was no significant difference in survival between the 
two groups (Figure S16; Table 1 rows 9 and 10), although there was weak evidence of an 
effect implying longer OS with transplant. 
We hypothesized that the seven-gene signature should have minimal predictive ability in 
VRD-treated patients. As expected, we saw no difference between the outcomes for patients 
assigned to the bortezomib-best or lenalidomide-best groups when those patients were treated 
with VRD. This was true both for OS (Figure 3F; Table 1, row 11) and for PFS (Figure 
S15B; Table 1, row 12). This lack of predictive ability was also seen in multivariate analyses 
incorporating clinical features (Table S13, rows 5 and 6). 
The seven-gene signature performs well in other independent datasets 
We were keen to test how our signature would perform in other non-transplant settings, such 
as relapsed disease. However, being limited by the availability of publicly-available RNA-
Seq data, we turned to microarray data. There were two suitable datasets available. One 
comprised samples from patients with relapsed-refractory myeloma treated with single-agent 
bortezomib26 (the Millennium dataset). The second contained transcriptomic data from a 
small series of patients with PCL treated with RD27 (the PCL dataset). We reasoned that, 
within the Millennium dataset, patients assigned to the bortezomib-best class should have a 
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better survival, whereas within the PCL dataset, those assigned to the lenalidomide-best class 
should have the superior outcome. 
Signature assignments behaved as predicted. In the Millennium dataset the bortezomib-best 
group had a superior PFS (Figure 4A; Table 1, row 13) and OS (Figure 4B; Table 1, row 14) 
to the lenalidomide-best group. These results were robust to training/validation splits (Figure 
4C; Table 2, rows 5 and 6). In the PCL dataset, those predicted to be in the lenalidomide-best 
group had a superior PFS (Figure 4D; Table 1, row 15) and OS (Figure 4E; Table 1, row 16) 
than patients assigned to the bortezomib-best group. Again, the signature was robust, with 
little influence from the training/validation split (Figure 4F; Table 2, rows 7 and 8). 
The seven-gene signature loses predictive power in patients proceeding to ASCT 
The bortezomib-good patients in the PADIMAC training set avoided ASCT because of their 
good response, according to trial protocol. We had thus far confined testing in external 
datasets to patients who had not had ASCT. We wondered whether the signature would retain 
its predictive power in patients proceeding to ASCT or whether transplant would overcome 
the survival differences between correctly and incorrectly treated patients. The HOVON-
64/GMMG-HD4 phase III trial49 compared patients with newly diagnosed myeloma treated 
with conventional chemotherapy versus those treated with PAD. Both groups of patients 
proceeded to ASCT. 
We used our signature to make bortezomib-best and lenalidomide-best assignments in 
patients who had received PAD. We reasoned that, if the signature retained its predictive 
power in the ASCT setting, we would see superior survival in those patients assigned to the 
bortezomib-best group. This was not the case, however, and we saw no significant difference 
in either PFS (Figure 5A; Table 1, row 17) or OS (Figure 5B; Table 1, row 18) between the 
different signature assignments. 
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As a further check for the specificity of the signature, we also tested its predictive value in the 
dexamethasone-only arm. As anticipated, there was no difference in PFS between those 
patients predicted to be bortezomib-good and those predicted to be lenalidomide-good 
(Figure S17A). However, patients predicted to be bortezomib-good had a superior OS in this 
arm (Figure S17B). This is likely to be because patients receiving dexamethasone were 
eligible to receive cross-over bortezomib upon disease progression. 
Discussion  
If it can be realized, precision cancer medicine will benefit patients in terms of improved 
efficacy and reduced toxicity and will benefit society in terms of better management of 
limited drug budgets. Transcriptomics has considerable promise in this area.50 There are 
signatures that predict for overall prognosis in cancer,51-62 including myeloma,4-12 and 
signatures that predict response to individual therapies.63-67 However, we are not aware of any 
published signature that can be used to rationally select between different active cancer 
therapies. Remarkable improvements in myeloma outcome over recent years have been seen 
thanks to the introduction of multiple novel agents, but this has been associated with 
increasing costs of treatment.68 Therefore, precision medicine is arguably of particular 
importance in this disease to help navigate through the increasing armamentarium of 
available therapies. 
Herein, we describe the derivation and testing of a seven-gene signature that can be used to 
select between bortezomib-based or RD therapy in myeloma patients not undergoing ASCT. 
Patients treated correctly according to the signature in the CoMMpass dataset had a 69.7 
months 3-year OS, similar to the outcome of patients treated with VRD, probably the current 
standard care for transplant-ineligible patients.3 These comparisons have to be viewed with 
caution, as CoMMpass is not a clinical trial. Nevertheless, the OS seen in the VRD group 
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(74.5 months) is similar to that of the VRD-treated patients in the trial of Durie et al. (75.0 
months).3 Furthermore, there was no evidence that VRD-treated patients represented a poor-
prognosis cohort in CoMMpass; there were no significant differences between the rates of 
poor-risk cytogenetics or ISS in the VRD group and the bortezomib- or RD-treated groups, 
and non-inferior survival was maintained in a multivariate model incorporating ISS. 
If the outcome of rationally selected bortezomib- or lenalidomide-based therapy is equivalent 
to that of VRD, it would be important to consider why this might be. It may be that many 
patients treated with VRD are predominantly benefiting from just the bortezomib or the 
lenalidomide. Alternatively, it might be that any gains in combining the drugs are offset by 
increased toxicity, particularly in older or frailer patients. It is important to note that the 
reciprocal performance that we observe is an intrinsic property of the signature and not 
simply because bortezomib-sensitivity is automatically associated with lenalidomide-
resistance (and vice versa). This is clearly not the case in clinical practice, nor is it consistent 
with the existence of multiple treatment-agnostic prognostic signatures in myeloma. 
Although PADIMAC was a trial for transplant-eligible patients, the signature was trained on 
patients who had had a good response in the absence of ASCT. Therefore, our initial test set 
comprised patients who were transplant-ineligible (there were no datasets from transplant-
eligible patients who did not proceed to transplant). Transplant-ineligible patients would be 
the most obvious to benefit following successful translation of the signature to the clinic. 
When tested in transplant-eligible patients who had received PAD and ASCT in the 
HOVON-64/GMMG-HD4 trial, the signature lost its predictive ability, implying that 
transplant can overcome the effect of receiving the “wrong” treatment. An interesting 
question would be whether receiving the correct predicted treatment without transplant is 
equivalent to ASCT. We saw no survival difference between transplant-ineligible patients 
treated correctly with bortezomib and all transplant-eligible patients treated with bortezomib 
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followed by ASCT. However, there was weak evidence of an effect suggesting better OS for 
patients who had a transplant. 
There are limitations of our signature that need to be overcome before employment in a 
clinical trial. The signature assigns approximately one-quarter to one-third of patients to the 
bortezomib-best group and the remainder to the lenalidomide-best group by default. It may be 
that this larger group is heterogeneous, with some patients having poorer prognosis or multi-
clonal disease and thus requiring VRD or the addition of other novel agents. Others may 
benefit equally from bortezomib- or lenalidomide-based treatments, regardless of signature 
assignment. Our signature was not capable of identifying these different groups (data not 
shown). Our external test cohorts were fairly small, owing to the lack of publicly-available 
and appropriate test datasets, and prospective validation of our signature will be needed. This 
will probably require the development of a quantitative PCR or focused sequencing panel, 
though the small number of genes in the signature means that this should be feasible. Finally, 
it is not clear to what extent our signature represents a drug effect or a class effect, because of 
the lack of publicly available test datasets involving patients treated with alternative PIs or 
IMiDs. Future data may become available from clinical trials in which expression profiling 
has been incorporated into the protocol. 
We believe that our signature has the potential to move the myeloma field towards rational 
therapy decisions for transplant-ineligible patients in the future. It is essential that myeloma 
genomic datasets with relevant clinical outcome data continue to be made publicly available 
to allow refinement and prospective validation of these approaches. This will require the 
ongoing support of the myeloma research community. 
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Tables 
Row Treatment 
(dataset) 
Comparison n1 n2 Median 
survival 1 
(months) 
Median 
survival 2 
(months) 
HR (CI) p-value 
1 Bortezomib-based 
(C) 
Bortezomib-standard vs. 
bortezomib-good (PFS) 
108 39 21.9 36.2 0.37 
(0.17-0.81) 
0.0063 
2 RD (C) Bortezomib-standard vs. 
bortezomib-good (PFS) 
29 11 Not 
reached 
18.8 2.35 
(0.76-7.63) 
0.16 
3 Bortezomib-based 
or RD (C) 
Incorrectly-treated vs. 
correctly-treated (PFS) 
119 68 20.1 Not 
reached 
0.40 
(0.23-0.72) 
0.0012 
4 Bortezomib-based 
or RD (C) 
Incorrectly-treated vs. 
correctly-treated (OS) 
119 68 30.7 Not 
reached 
0.41 
(0.21-0.80) 
0.0049 
5 Bortezomib-based 
or RD or VRD (C) 
All VRD vs. all non-
VRD (PFS) 
208 187 43.7 26.0 1.50 
(1.06-2.13) 
0.02 
6 Bortezomib-based 
or RD or VRD (C) 
All VRD vs. all non-
VRD (OS) 
208 187 Not 
reached 
37.8 2.05 
(1.34-3.13) 
0.00084 
7 Bortezomib-based 
or RD or VRD (C) 
All VRD vs. non-VRD 
correctly-treated (OS) 
208 68 Not 
reached 
Not 
reached 
1.12 
(0.58-2.13) 
0.74 
8 Bortezomib-based 
or RD or VRD (C) 
All VRD vs. non-VRD 
correctly-treated (PFS) 
208 68 43.7 Not 
reached 
0.86 
(0.50-1.47) 
0.57 
9 Bortezomib-based 
+/- ASCT 
Bortezomib correctly 
treated vs. ASCT (PFS) 
47 39 36.6 36.2 1.16 0.75 
10 Bortezomib-based 
+/- ASCT 
Bortezomib correctly 
treated vs. ASCT (OS) 
47 39 43.7 Not 
reached 
3.10 0.08 
11 VRD (C) Lenalidomide-best vs. 
bortezomib-best (OS) 
164 44 Not 
reached 
Not 
reached 
1.41 
(0.69-2.90) 
0.36 
12 VRD (C) Lenalidomide-best vs. 
bortezomib-best (PFS) 
164 44 43.7 45.4 1.11 
(0.62-1.92) 
0.74 
13 Bortezomib alone 
(M) 
Lenalidomide-best vs. 
bortezomib-best (PFS) 
135 38 4.14 4.77 0.66 
(0.43-1.0) 
0.04 
14 Bortezomib alone 
(M) 
Lenalidomide-best vs. 
bortezomib-best (OS) 
148 40 15.2 25.8 0.57 
(0.53-0.91) 
0.01 
15 RD (PCL)  Lenalidomide-best vs. 
bortezomib-best (PFS) 
8 10 Not 
reached 
1.0 Not defined* 2.52x10-5 
16 RD (PCL) Lenalidomide-best vs. 
bortezomib-best (OS) 
8 10 Not 
reached 
12.5 Not defined* 0.0013 
17 PAD/ASCT (H) Lenalidomide-best vs. 
bortezomib-best (PFS) 
84 57 26.6 31.8 0.91 
(0.60-1.37) 
0.63 
18 PAD/ASCT (H) Lenalidomide-best vs. 
bortezomib-best (OS) 
85 58 Not 
reached 
Not 
reached 
0.73 
(0.40-1.34) 
0.30 
Table 1 – Cox regression results for survival comparisons. All signature assignments were based on the 
seven-gene signature. Correctly-treated patients (rows 3-6) were those predicted by the signature as 
lenalidomide-best and who were treated with RD or those predicted as bortezomib-best and treated with 
bortezomib-based therapy. The datasets are CoMMpass (C), Millennium (M), plasma cell leukemia (PCL), 
or HOVON/GMMG (H). The numbers in the first group in the comparison (n1) and second group in the 
comparison (n2) are given. The hazard ratio (HR) is that of the second group versus the first group. CI – 
confidence interval. *The HR for the PCL group is not defined because all patients in group 2 progressed 
before any progressions in group 1 (row 11) or because there were no deaths in group 1 (row 12). 
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Row Treatment (dataset) Comparison Median HR 
observed 
Median HR 
null 
Mann-
Whitney U 
p-value 
1 Bortezomib-based (C) Bortezomib-standard vs. 
bortezomib-good (PFS) 
0.44 0.94 348 5.67x10-30 
2 RD (C) Bortezomib-standard vs. 
bortezomib-good (PFS) 
2.01 0.93 1526 1.91x10-17 
3 Bortezomib-based or 
RD (C) 
Incorrectly-treated vs. correctly-
treated (PFS) 
0.48 0.92 185 5.44x10-32 
4 Bortezomib-based or 
RD (C) 
Incorrectly-treated vs. correctly-
treated (OS) 
0.46 0.85 3 2.52x10-34 
5 Bortezomib alone (M) Lenalidomide-best vs. 
bortezomib-best (PFS) 
0.68 0.97 489 2.75x10-28 
6 Bortezomib alone (M) Lenalidomide-best vs. 
bortezomib-best (OS) 
0.53 1.00 108 5.67x10-33 
7 RD (PCL)  Bortezomib-best vs. 
lenalidomide-best (PFS) 
0.24 0.83 1334 2.84x10-19 
8 RD (PCL) Bortezomib-best vs. 
lenalidomide-best (OS) 
0.20 0.96 1117 1.98x10-21 
Table 2 – Mann-Whitney-Wilcoxon results testing the robustness of the seven-gene signature to 
assignments across multiple (n=100) training/validation data splits. Each dataset is from CoMMpass (C), 
Millennium (M), plasma cell leukemia (PCL), or HOVON/GMMG (H). One hundred assignments were made 
in each dataset by the seven-gene signature following random training/validation splits (observed). Each of 
these assignments was then permuted to maintain assignment ratios (null). The performance of the observed 
and null assignments for predicting progression-free survival (PFS) and overall survival (OS) was compared 
in terms of hazard ratios (HRs) by the Mann-Whitney-Wilcoxon test. The hazard ratio (HR) is that of the 
second group versus the first group. 
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Figure Legends 
Figure 1 – Fusion events, key single nucleotide variations (SNVs), and translocation-
cyclin D (TC) classification of PADIMAC data. Each column represents a single sample. 
Samples are arranged into and color-coded by their TC classes (shown at the bottom). (A) 
Numbers of fusion events in each sample. (B) Key SNVs in each sample. (C) Expression of 
genes whose dysregulation is associated with TC classification in each sample. 
Figure 2 – A seven-gene signature accurately predicts response to bortezomib-based 
therapy in PADIMAC and the independent CoMMpass datasets. (A) Matthews 
correlation coefficients (MCCs) and F-measures of bortezomib-good assignments by 4-11 
gene signatures derived from synthetic annealing, following cross-validation within the 
PADIMAC dataset. (B) and (C) MCCs and F-measures of bortezomib-good assignments by 
the seven-gene signature following multiple (n=100) cross-validations within the PADIMAC 
dataset (Signature) compared to the MCC and F-measures of permuted assignments (Null). 
The p-values are those of the Wilcoxon-Mann-Whitney test, under the null hypothesis that 
the distributions of observed and null performances are the same. (D) Kaplan-Meier plot 
showing the progression-free survival of patients who received bortezomib-based therapy 
within CoMMpass (n=147) and who were predicted to benefit (n=39; broken line) or not 
(n=108; solid line) from bortezomib-based therapy by the seven-gene signature following 
training in PADIMAC. The p-value and hazard ratios (HRs) are those obtained from Cox 
regression analysis. (E) HRs for disease progression of bortezomib-good versus bortezomib-
standard patients who received bortezomib-based therapy in CoMMpass. Predictions were 
made by the seven-gene signature, trained in PADIMAC, and followed repeated (n=100) 
training/validation splits (Signature). The HRs are compared with a null dataset of HRs 
obtained following permutations of the assignments (Null). The p-value is that of the 
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Wilcoxon-Mann-Whitney test, under the null hypothesis that the distributions of observed 
and null performances are the same. 
Figure 3 – The seven-gene signature can be used as a classifier to select between 
bortezomib-based therapy and lenalidomide/dexamethasone (RD) in the independent 
CoMMpass dataset. (A) Kaplan-Meier plot showing the progression-free survival (PFS) of 
patients who received RD therapy (n=40) within CoMMpass and who were predicted to 
benefit (n=11; broken line) or not (n=29; solid line) from bortezomib-based therapy by the 
seven-gene signature following training in PADIMAC. The p-value and hazard ratios (HRs) 
are those obtained from Cox regression analysis. (B) HRs for disease progression of 
bortezomib-good versus bortezomib-standard patients who received RD in CoMMpass. 
Predictions were made by the seven-gene signature, trained in PADIMAC, and followed 
repeated (n=100) training/validation splits (Signature). The HRs are compared with a null 
dataset of HRs obtained following permutations of the assignments (Null). The p-value is that 
of the Wilcoxon-Mann-Whitney test, under the null hypothesis that the distributions of 
observed and null performances are the same. (C) Kaplan-Meier plot showing the PFS of 
patients who received bortezomib-based therapy or RD within CoMMpass (n=187) and who 
received the correct (n=68; broken line) or incorrect (n=119; solid line) therapy predicted by 
the seven-gene signature following training in PADIMAC. The p-value and HR are those 
obtained from Cox regression analysis. (D) Kaplan-Meier plot showing the overall survival 
(OS) of patients who received bortezomib-based therapy or RD within CoMMpass (n=187) 
and who received the correct (n=68; broken line) or incorrect (n=119; solid line) therapy 
predicted by the seven-gene signature following training in PADIMAC. The p-value and HR 
are those obtained from Cox regression analysis. (E) Kaplan-Meier plot showing the OS of 
patients (n=276) who received bortezomib/lenalidomide/dexamethasone (VRD; n=208; solid 
line) or who received bortezomib-based therapy or RD within CoMMpass and who received 
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the correct therapy predicted by the seven-gene signature (n=68; broken line) following 
training in PADIMAC. The p-value and HR are those obtained from Cox regression analysis. 
(F) Kaplan-Meier plot showing the OS of patients who received VRD in CoMMpass (n=208; 
solid line) and who were predicted to benefit from RD (n=164; solid line) or from 
bortezomib-based therapy (n=44; broken line) by the seven-gene signature following training 
in PADIMAC. The p-value and HR are those obtained from Cox regression analysis. 
Figure 4 – The seven-gene signature accurately predicts bortezomib- or lenalidomide-
responsiveness in further independent datasets. (A) Kaplan-Meier plot showing the 
progression-free survival (PFS) of patients who received single-agent bortezomib within the 
Millennium studies (n=173) and who were predicted to benefit from bortezomib-based 
therapy (n=38; broken line) or from RD therapy (n=135; solid line) by the seven-gene 
signature following training in PADIMAC. The p-value and hazard ratios (HRs) are those 
obtained from Cox regression analysis. (B) Kaplan-Meier plot showing the overall survival 
(OS) of patients who received single-agent bortezomib within the Millennium studies 
(n=188) and who were predicted to benefit from bortezomib-based therapy (n=40; broken 
line) or RD therapy (n=148; solid line) by the seven-gene signature following training in 
PADIMAC. The p-value and HRs are those obtained from Cox regression analysis. (C) HRs 
for PFS and OS of patients predicted to benefit from bortezomib-based therapy who received 
bortezomib in the Millennium studies. Predictions were made by the seven-gene signature, 
trained in PADIMAC with repeated (n=100) training/validation splits (Signature). The HRs 
are compared with a null dataset of HRs obtained following permutations of the assignments 
(Null). The p-values are those of the Wilcoxon-Mann-Whitney test, under the null hypothesis 
that the distributions of observed and null performances are the same. (D) Kaplan-Meier plot 
showing the PFS of patients who received RD within the plasma cell leukemia study (n=18) 
and who were predicted to benefit (n=8; solid line) or not (n=10; broken line) from RD 
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therapy by the seven-gene signature following training in PADIMAC. The p-value is that 
obtained from Cox regression analysis. (E) Kaplan-Meier plot showing the OS of patients 
who received RD within the plasma cell leukemia study (n=18) and who were predicted to 
benefit (n=8; solid line) or not (n=10; broken line) from RD therapy by the seven-gene 
signature following training in PADIMAC. The p-value is that obtained from Cox regression 
analysis. (F) HRs for PFS and OS of patients predicted to benefit from lenalidomide-based 
therapy and who received RD in the plasma cell leukemia study. Predictions were made by 
the seven-gene signature, trained in PADIMAC with repeated (n=100) training/validation 
splits (Signature). The HRs are compared with a null dataset of HRs obtained following 
permutations of the assignments (Null). The p-value is that of the Wilcoxon-Mann-Whitney 
test, under the null hypothesis that the distributions of observed and null performances are the 
same. 
Figure 5 – The signature loses predictive ability in the transplant setting. (A) Kaplan-
Meier plot showing the progression-free survival (PFS) of patients who received bortezomib, 
adriamycin, and dexamethasone (PAD) within the HOVON-65/GMMG-HD4 study (n=143) 
prior to autologous stem cell transplant (ASCT) and who were predicted to benefit from 
bortezomib-based therapy (n=58; broken line) or from RD therapy (n=85; solid line) by the 
seven-gene signature following training in PADIMAC. The p-value and hazard ratios (HRs) 
are those obtained from Cox regression analysis. (B) Kaplan-Meier plot showing the overall 
survival (OS) of patients who received PAD within the HOVON-65/GMMG-HD4 study 
(n=143) prior to ASCT and who were predicted to benefit from bortezomib-based therapy 
(n=58; broken line) or RD therapy (n=85; solid line) by the seven-gene signature following 
training in PADIMAC. The p-value and HRs are those obtained from Cox regression 
analysis. 
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